Briefing
Comparative analysis of ctDNA-MRD and MVI in predicting postoperative recurrence of hepatocellular carcinoma: a prospective multicenter cohort study
This prospective multicenter study enrolled 152 patients with BCLC stage 0-B hepatocellular carcinoma undergoing curative resection and monitored tumor-informed ctDNA MRD at 1, 4, and 7 months after surgery. Longitudinal MRD positivity (newly positive or persistently positive versus clearance or persistently negative) independently predicted recurrence (HR 12.45) and preceded radiologic recurrence in 87.5% of cases, with a median lead time of 86 days. Time-dependent AUCs for longitudinal MRD were 0.785-0.849, compared with 0.655-0.752 for microvascular invasion.
- Design: Evidence level 2
- Assay: Not named in the abstract
Hepatology InternationalPubMed 42955557DOI 10.1007/s12072-026-11163-8